Drug Trial Radar · NCT02426034
A Study of Apatinib Tablets in the Treatment of Advanced or Metastatic Gastric Cancer
Last checked: Nov 19, 2026Latest source record: Jul 1, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
2,004
Actual
Start
May 15, 2015
Primary completion
May 29, 2020
Study completion Sep 3, 2020
Sponsor
- Lead sponsor
- Jiangsu HengRui Medicine Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Apr 24, 2015
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The large-scale phase IV study aims to verify the safety and efficacy of apatinib in patients with advanced gastric cancer or gastroesophageal junction adenocarcinoma after failure of two lines of chemotherapy. Apatinib initiated at a recommended dose of 850mg. However, the starting dose was decided by investigator's choice based on patients' condition. Dose interruption and dose reduction were allowed according to the product label. Treatment continued until disease progression, intolerable toxicity, withdrawal of informed consent, or at investigators' discretion. The primary endpoint was safety, which was assessed by recording the incidence and severity of adverse events.
Conditions
- Advanced Gastric or Gastroesophageal Junction Adenocarcinoma
Interventions
ApatinibTabletsDrug
Apatinib Tablets, recommended dose of 850mg
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety, which was assessed by recording the incidence and severity of adverse eventsTime frame: between first dose of apatinib and up to 30 days after the last dose of apatinib
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Nanjin Military 81 Hosiptal
Nanjing, Jiangsu, China
Fudan University cancer hospital
Shanghai, Shanghai Municipality, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.